New Diabetes Care Standards; Near 40% Ditch T2D Meds; Zepbound Hits Shelves

The American Diabetes Association released its 2024 installment of the Standard of Care in Diabetes, featuring updates on screening, obesity drugs, new technology, and teplizumab (Tzield). (Diabetes Care)

Almost 40% of adults with type 2 diabetes discontinued their second-line medication within a year of starting it. (American Journal of Managed Care)

Patients’ adherence to semaglutide for obesity was higher compared with previous weight-loss drugs, including naltrexone-bupropion (Contrave) and phentermine-topiramate (Qsymia), a retrospective study found. (Obesity)

Tandem Diabetes Care launched updated t:slim X2 insulin pump software for use with the Dexcom G7 continuous glucose monitor.

A New York Times investigation suggested that Bellevue Hospital in New York performed a high volume of bariatric surgeries on vulnerable individuals, including prisoners and other inappropriate patients.

The FDA established the new Genetic Metabolic Diseases Advisory Committee to focus on “complicated issues” related to genetic metabolic disease drug development.

In a secondary analysis of EMPA-KIDNEY, empagliflozin (Jardiance) cut the risk of kidney disease progression in those with a wide range of non-diabetic disease. (Lancet Diabetes & Endocrinology)

Nations should increase taxes on alcohol and sugar-sweetened beverages as a way to incentivize healthier behaviors, the World Health Organization said.

Eli Lilly’s tirzepatide (Zepbound), the rebranded weight-loss version of its diabetes drug, is now available in pharmacies, less than a month after FDA approval. (Forbes)

The U.S. Supreme Court declined to hear a case challenging a 2018 Washington state law banning conversion therapy for minors, an approach the American Medical Association said “is not based on medical and scientific evidence.” (NPR)

Bempedoic acid cut down on LDL cholesterol, high-sensitivity C-reactive protein, plus risk of cardiovascular events in people with diabetes, according to a prespecified CLEAR Outcomes trial analysis. (Lancet Diabetes & Endocrinology)

Exposure to the endocrine-disrupting perfluoroalkyl substances was tied to changes in bone mineral density in adolescents and young adults. (Environmental Research)

Please enable JavaScript to view the

comments powered by Disqus.